Merck & Co.
American multinational pharmaceutical company
Follow Merck & Co. on Notably News to receive short updates to your email — rarely!
| October 2024 | Merck announced the acquisition of Modifi Biosciences for $1.3 billion. |
| September 20 2024 | The United States Court of Appeals for the Third Circuit overturned the previous federal law preemption decision, holding that federal law did not block plaintiffs' state law claims against Merck over Fosamax. |
| July 2024 | Merck completed the acquisition of EyeBio for $3 billion. |
| April 2024 | Merck completed the acquisition of Abceutics for $208 million. |
| January 2024 | Merck announced the acquisition of Harpoon Therapeutics for $680 million, expanding its oncological drug portfolio with HPN328 and T-cell activation technologies. |
| 2023 | Company's position in the Forbes Global 2000 list improved to 73rd place. |
| December 2023 | Merck partnered with Owkin to develop AI-powered digital pathology diagnostics for identifying patients suitable for immunotherapies. |
| April 2023 | Merck announced the acquisition of Prometheus Biosciences Inc for $10.8 billion. |
| 2022 | Ranked 71st on the Fortune 500 list based on 2021 revenues. |
| 2022 | Ranked 87th on the Forbes Global 2000 list based on 2021 revenues. |
| December 2022 | Merck announced a licensing deal with Kelun-Biotech of China to expand its early cancer pipeline with antibody-drug conjugates. |
| September 2022 | Merck announced the acquisition of Vence, a livestock management company, for an undisclosed sum. |
| March 2022 | Merck defeated approximately 500 lawsuits over Fosamax in New Jersey when U.S. District Judge Freda L. Wolfson ruled that the plaintiffs' lawsuit was preempted by federal law. |
| 2021 | Reuters investigation revealed Propecia's serious side effects, including over 700 reported incidences of suicidal thoughts and 110 deaths, highlighting Merck's long-standing failure to disclose these risks on the drug's label. |
| September 2021 | Merck announced the acquisition of Acceleron Pharma for $11.5 billion, gaining control over Sotatercept for pulmonary hypertension treatment. |
| July 2021 | Robert M. Davis became CEO, succeeding Kenneth Frazier, who became executive chairman. Merck also completed the corporate spin-off of Organon & Co. |
| July 2021 | Merck completed the corporate spin-off of Organon & Co. |
| July 2021 | Robert M. Davis became CEO, succeeding Kenneth Frazier, who became executive chairman. |
| June 2021 | U.S. government agreed to purchase 1.7 million doses of Molnupiravir for $1.2 billion if approved for COVID-19 treatment. |
| April 2021 | Merck acquired Pandion Therapeutics for $1.85 billion, expanding its offering in treating autoimmune diseases. |
| March 2021 | Merck Head of Corporate Affairs Petra Wicklandt represented the company at the Munich Security Conference, participating in a tabletop exercise on monkeypox response. |
| February 2021 | Merck Animal Health acquired PrognostiX Poultry. |
| November 2020 | Merck announced the acquisition of VelosBio for $2.75 billion, a developer of VLS-101 for cancer treatment, and OncoImmune for $425 million for its COVID-19 treatment candidate CD24Fc. |
| September 2020 | Merck served as a Conference Supporter for the Virtual ISPOR Asia Pacific conference, demonstrating the company's engagement in professional health research and pharmaceutical industry events. |
| September 2020 | Merck acquired $1 billion of Seattle Genetics common stock and agreed to co-develop ladiratuzumab vedotin. |
| August 2020 | Merck Animal Health acquired IdentiGEN, a company engaged in DNA-based animal traceability. |
| June 2020 | Merck Animal Health acquired Quantified Ag, a data and analytics company monitoring cattle health. |
| June 2020 | Merck acquired Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases including COVID-19 and cancer. |
| April 2020 | The Federal Supreme Court of Switzerland ruled that MSD's global website usage of the 'Merck' brand could potentially violate Merck's trademark rights in Switzerland. |
| March 2020 | Merck was recognized at the inaugural Manufacturing Awards by New Jersey Business magazine and the New Jersey Business and Industry Association. |
| January 2020 | Merck acquired ArQule, a developer of BTK inhibitor ARQ 531, for $2.7 billion. |
| December 2019 | Merck Animal Health acquired Vaki, an aquaculture company, from Pentair. |
| November 2019 | Merck acquired Calporta, which focused on Parkinson's and Alzheimer's treatments. |
| June 2019 | Merck announced it would acquire Tilos Therapeutics for up to $773 million. |
| May 2019 | Merck announced it would acquire Peloton Therapeutics for up to $2.2 billion. |
| April 2019 | Merck acquired Immune Design for approximately $300 million and Antelliq Group for $2.4 billion. |
| June 2018 | Merck acquired Viralytics, an Australian viral cancer drug company, for AUD$502 million. |
| 2017 | Merck announced a biosimilar to Remicade called Renflexis, expanding their portfolio of treatments for autoimmune disorders. |
| September 2017 | Merck announced it would acquire Rigontec, a developer of a candidate to target the retinoic acid-inducible gene I pathway, for $554 million. |
| April 2017 | Merck Animal Health acquired Vallée S.A., a Brazilian animal health product manufacturer. |
| 2016 | The High Court of Justice in the United Kingdom ruled that MSD breached an agreement with its former parent company and that only Merck of Darmstadt is entitled to use the Merck name in the United Kingdom. |
| January 2016 | MSD filed a federal lawsuit in the United States, accusing its former parent company of trademark infringement through increased usage of 'Merck KGaA' and 'MERCK' in US branding and social media. |
| 2015 | Merck was sued by Hagens Berman, a consumer-rights law firm, over a wrongful death linked to Propecia. |
| 2015 | Merck Group adopted a new logo and announced it would be more aggressive about protecting its brand, initiating litigation against Merck & Co. over the use of the Merck name. |
| January 2015 | Merck acquired Cubist Pharmaceuticals for $9.5 billion. |
| December 2014 | Merck acquired Swiss biotechnology company OncoEthix for up to $375 million. |
| September 4 2014 | The US Food and Drug Administration (FDA) approved Pembrolizumab (Keytruda) as a breakthrough therapy for melanoma treatment, marking a significant milestone in cancer immunotherapy. |
| August 2014 | Merck acquired Idenix Pharmaceuticals for $3.85 billion. |
| December 2013 | Merck agreed to pay $27.7 million to 1,200 plaintiffs in a class action lawsuit over Fosamax, alleging the drug caused osteonecrosis of the jaw. Prior to this settlement, Merck had won 3 of 5 bellwether trials, with approximately 4,000 cases still pending. |
| December 2013 | Merck agreed to pay $27.7 million to 1,200 plaintiffs in a class action lawsuit related to Fosamax causing osteonecrosis of the jaw, after previously prevailing in 3 of 5 bellwether trials. |
|
We are only showing the most recent entries for this topic. |
|
This contents of the box above is based on material from the Wikipedia article Merck & Co., which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.